A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Details
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Eligibility
You can join if...
Inclusion Criteria:
-Patients must be 18 years of age or older
-Patients must have histologic or cytologic proof of pancreatic adenocarcinoma or adenosquamous carcinoma
Exclusion Criteria:
Patients must not have prior radiation therapy, chemotherapy, targeting therapy, investigational therapy or surgery for pancreatic cancer
-Patients must not be pregnant or nursing